Silexion Therapeutics Corp (SLXN) – Key Developments
Silexion Therapeutics Corp, a U.S. health‑care company listed on the Nasdaq, experienced a significant 61 % increase in its after‑hours trading price on September 29, 2026. The surge was reported by Benzinga (2026‑09‑29) and followed the disclosure of promising preclinical results for its lead compound SIL204.
Preclinical Findings for SIL204
On September 28, 2026, Silexion released detailed preclinical data concerning SIL204, its flagship drug candidate targeting KRAS‑driven cancers. According to the company’s statement on the same day, the data demonstrate a key mechanism for endogenous systemic uptake of the drug, providing evidence that SIL204 can effectively reach tumor tissues in relevant animal models. This information was reiterated in a separate release on the same day and corroborated by a summary from Investing.com.
Implications for the Company
- Scientific Validation: The demonstration of efficient systemic delivery in preclinical models strengthens the therapeutic promise of SIL204 for patients with KRAS‑mutated malignancies.
- Market Reaction: The 61 % after‑hours rise in share price reflects investor optimism regarding the clinical development trajectory of SIL204.
- Financial Position: As of the latest close on September 27, the company trades at $0.248 per share, with a market capitalization of approximately $1.45 million. The price‑earnings ratio is negative at –0.01, reflecting the company’s ongoing investment in research rather than profitability.
Current Status
Silexion is positioned to advance SIL204 toward clinical trials, contingent on regulatory approvals and further development milestones. The company’s recent announcements highlight a critical step in validating the drug’s delivery mechanism, which is essential for its intended therapeutic applications.
